NIMH Clinical Trial

NIMH AV-101 Phase 2 Monotherapy Study for MDD

The U.S. National Institute of Mental Health (NIMH), part of the U.S. National Institutes of Health (NIH), is currently evaluating AV-101 in a Phase 2 monotherapy study for the treatment of MDD. This study is being conducted by Dr. Carlos Zarate of the NIMH and fully funded by the NIMH.

Study Center and Contact

Site Contact Principal Investigator
National Institutes of Health Clinical Center
9000 Rockville Pike
Bethesda, MD 20892
United States
Libby Jolkovsky
(877) 646-3644
libby_jolkovsky@nih.gov

Carlos A Zarate, M.D.

For more information about the study, please visit www.clinicaltrials.gov.